zifeng-ai/TrialReviewBench huggingface dataset:
Study: TEAM
Study design: RCT phase III
Primary endpoint: DFS
Menopausal status: Postmenopausal patients
Treatment arms: Patients randomized in a 1 : 1 ratio to receive 5 years of oral exemestane monotherapy or a sequential scheme of oral tamoxifen followed by exemestane for a total duration of 5 yearsa
HER2-positive patients, n: 525 (12.3%)
Total patients, N: 9779
Study: ATAC
Study design: RCT phase III
Primary endpoint: DFS
Menopausal status: Postmenopausal patients
Treatment arms: Patients randomized in a 1 : 1 : 1 ratio to receive anastrozole, tamoxifen or anastrozole plus tamoxifen
HER2-positive patients, n: 178 (10.6%)
Total patients, N: 5880
Study: BIG 1-98
Study design: RCT phase III
Primary endpoint: DFS
Menopausal status: Postmenopausal patients
Treatment arms: Patients randomized in a 1 : 1 : 1 : 1 ratio to receive monotherapy with tamoxifen or letrozole for five years or sequential therapy comprising letrozole followed by tamoxifen or vice versab
HER2-positive patients, n: 389 (6.3%)
Total patients, N: 8010
Study: SOFT
Study design: RCT phase III
Primary endpoint: DFS
Menopausal status: Premenopausal patients
Treatment arms: Patients in a 1 : 1 : 1 ratio to receive tamoxifen, tamoxifen plus ovarian suppression or exemestane plus ovarian suppression for 5 years
HER2-positive patients, n: 366 (11.9%)
Total patients, N: 3066
Study: TEXT
Study design: RCT phase III
Primary endpoint: DFS
Menopausal status: Premenopausal patients
Treatment arms: Patients were randomized in a 1 : 1 ratio to receive tamoxifen plus ovarian suppression, or exemestane plus ovarian suppression for 5 yearsc
HER2-positive patients, n: 329 (12.3%)
Total patients, N: 2672
Study: ALTTO
Study design: RCT phase III
Primary endpoint: DFS
Menopausal status: Premenopausal patients (n = 1715, 47.6%) and postmenopausal (n = 1888, 52.4%)e
Treatment arms: Patients were randomized in a 1 : 1 : 1 : 1 ratio to one of the following 1-year duration adjuvant anti-HER2 treatment arms: trastuzumab alone, lapatinib alone or trastuzumab followed by lapatinib and trastuzumab plus lapatinibd
HER2-positive patients, n: 6273 (100%) of them 57.4%, n = 3603, hr positivef
Total patients, N: 6273